REG - Wellnex Life Limited - Chair AGM Speech

Wellnex LifeAnnouncement

27/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251127:nRSa2570Ja&default-theme=true

RNS Number : 2570J  Wellnex Life Limited  27 November 2025

 

 

 

ASX/AIM
Announcement
27 November 2025

 

 

Wellnex Life Limited (ASX/AIM:WNX) ("Wellnex Life" or the "Company") announces
that Executive Chairman, Ash Vesali, is today providing the following update
to shareholders during company's annual general meeting.

 

Dear Shareholder,

 

It has now been two months since I stepped into the role of Executive
Chairman, and during this time I have had the opportunity to speak with many
of you, and I truly appreciate the candid conversations. My immediate priority
has been to establish a clear and disciplined framework to deliver a
successful turnaround and unlock the full potential of the business.

 

Wellnex owns a powerful brand, "Pain Away", with the capability to become
globally significant. Our structure and strategy are now firmly aligned around
accelerating its growth, both domestically and internationally.

 

Alongside this, we are continuing to expand our contract manufacturing
services and improve margins within this division. With the clear intent of
strengthening a recurring revenue stream that will play a key role in
improving cash flow.

 

To ensure we remain focused, we are deprioritising non-core assets,
consolidating underperforming brands, and ceasing investment in new brand
creation. This allows the team and I to remain laser-focused on our core
priorities, eliminating distractions and ensuring our resources are deployed
where they create the most value.

 

We have already taken meaningful steps to reduce operating costs and
transition to a leaner, more efficient structure. To date, we have:

·     streamlined headcount,

·     reassessed trade spends to ensure alignment with sales targets,
resulting in margin improvement, and

·     reviewed customer and supplier agreements to realign with our
strategic priorities.

 

As a result, we are on track to significantly reduce our annual operating
spend by up to 40% compared to the previous financial year, where total
spend was $10.8 million. A portion of these savings will be realised in FY26,
with the full run-rate benefit expected thereafter.

 

These initiatives position Wellnex on a path to achieve cashflow positive
performance and strengthening the foundation.

 

 

 

 

JOIN A BRIEFING

 

I will be hosting a live investor briefing on Monday 1 December 2025 at 11am
(AEDT) to outline our strategic roadmap and the growth plan for the near
future. Click here
(https://wellnexlife.investorportal.com.au/live-investor-briefing/)
(https://wellnexlife.investorportal.com.au/live-investor-briefing/) to
register for the briefing.
(https://wellnexlife.investorportal.com.au/live-investor-briefing/)

 

I am fully committed to driving the business forward and delivering results
for our shareholders. We are building a stronger and more focused Wellnex, and
I am confident in the path ahead.

 

Thank you for your ongoing support.

 

 

Ash Vesali

Executive Chairman

 

 

 

 

 

This ASX/AIM announcement has been authorised by the Board of Wellnex Life
Limited (ASX/AIM:WNX).

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX)
                Reach Markets

Ash Vesali
 
               T: 1300 805 941

Executive
Chairman
E: IR@reachmarkets.com.au (mailto:IR@reachmarkets.com.au)

E: ash.v@wellnexlife.com.au (mailto:ash.v@wellnexlife.com.au)

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson      Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)
swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)        Tel: +44 (0)20
3470 0470

David Hignell / Vadim Alexandre

 

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMGLBDBBSDDGUR



            Copyright 2019 Regulatory News Service, all rights reserved